Home LiteratureArticle Details
PMID: 15564543 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia.

The New England journal of medicine ·Vol. 351 ·No. 22 ·2004-11-25 ·Pages 2265-75

Laughlin MJ, Eapen M, Rubinstein P, Wagner JE, Zhang MJ, Champlin RE, Stevens C, Barker JN, Gale RP, Lazarus HM, Marks DI, van Rood JJ, Scaradavou A, Horowitz MM

Abstract

Data regarding the outcome of cord-blood transplantation in adults are scant, despite the fact that these grafts are increasingly used in adults. We compared the outcomes of the transplantation of hematopoietic stem cells from unrelated donors in adults with leukemia who had received cord blood that was mismatched for one HLA antigen (34 patients) or two antigens (116 patients), bone marrow that had one HLA mismatch (83 patients), and HLA-matched bone marrow (367 patients). We used Cox proportional-hazards models to analyze the data. Cord-blood recipients were younger and more likely to have advanced leukemia than were bone marrow recipients, and they received lower doses of nucleated cells. Hematopoietic recovery was slower with transplantation of mismatched bone marrow and cord blood than with matched marrow transplantations. Acute graft-versus-host disease (GVHD) was more likely to occur after mismatched marrow transplantation, and chronic GVHD was more likely to occur after cord-blood transplantation. The rates of treatment-related mortality, treatment failure, and overall mortality were lowest among patients who received matched marrow transplants. Patients who received mismatched bone marrow transplants and those who received mismatched cord-blood transplants had similar rates of treatment-related mortality (P=0.96), treatment failure (P=0.69), and overall mortality (P=0.62). There were no differences in the rate of recurrence of leukemia among the groups. There were no differences in outcome after cord-blood transplantation between patients with one HLA mismatch and those with two HLA mismatches. HLA-mismatched cord blood should be considered an acceptable source of hematopoietic stem-cell grafts for adults in the absence of an HLA-matched adult donor.

MeSH Terms
Acute Disease Adolescent Adult Age Distribution Blood Platelets/physiology Bone Marrow Transplantation/adverse effects,immunology,mortality Chronic Disease Cord Blood Stem Cell Transplantation/adverse effects,mortality Disease-Free Survival Female Fetal Blood/immunology,transplantation Graft vs Host Disease/etiology Hematopoietic Stem Cell Transplantation/adverse effects,mortality Histocompatibility Testing Humans Leukemia/immunology,mortality,therapy Male Middle Aged Myelodysplastic Syndromes/mortality,therapy Neutrophils/physiology Proportional Hazards Models Recurrence Retrospective Studies Survival Analysis Tissue Donors Treatment Outcome
Authors & Affiliations
14 authors, click to expand affiliations / ORCID
Laughlin Mary J
Case Comprehensive Cancer Center and University Hospitals of Cleveland Ireland Cancer Center, Cleveland, USA.
Eapen Mary
Rubinstein Pablo
Wagner John E
Zhang Mei-Jei
Champlin Richard E
Stevens Cladd
Barker Juliet N
Gale Robert P
Lazarus Hillard M
Marks David I
van Rood Jon J
Scaradavou Andromachi
Horowitz Mary M
Article Info
Journal
The New England journal of medicine
Abbr.
N Engl J Med
ISSN
1533-4406
Published
2004-11-25
Pages
2265-75
Language
English
Region
United States
NLM ID
0255562
Subset
IM
Grants
NCI NIH HHS · U24-CA76518 · United States
Corrections
CommentIn
CommentIn
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com